Skip to main content
Premium Trial:

Request an Annual Quote

GeneProt Licenses Protein to Novartis

NEW YORK, May 23 - GeneProt announced today that it has licensed its first protein to Novartis Pharma, as reported by ProteoMonitor in April.


The protein came out of the proteomics company's ongoing research collaboration with Novartis. At the end of 2001, GeneProt, based in Geneva, Switzerland, delivered six proteins to Novartis for further study, one of which the drug company now chose to license.


Bertrand Damour, GeneProt's president and CEO, told ProteoMonitor in April that the deal resulted in a "significant amount of cash" for the company.


"We look forward to further licenses in due course coming out of our collaboration with Novartis and from others," Damour said in a statement.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.